Premium
the influence of autologous lymphokine‐activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin‐2
Author(s) -
Albertini Mark R.,
Sosman Jeffrey A.,
Hank Jacquelyn A.,
Moore Karen H.,
Borchert Agnes,
Schell Kathleen,
Kohler Peter C.,
Bechhofer Robin,
Storer Barry,
Sondel Paul M.
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19901215)66:12<2457::aid-cncr2820661203>3.0.co;2-l
Subject(s) - medicine , regimen , toxicity , interleukin 2 , refractory (planetary science) , progressive disease , lymphokine activated killer cell , lymphokine , gastroenterology , hypoxemia , chemotherapy , surgery , immunology , cytokine , immune system , t cell , physics , astrobiology , interleukin 21
Twenty patients with refractory malignancies were treated with a protocol evaluating the addition of ex vivo ‐activated autologous lymphokine‐activated killer (LAK) cells to a clinically tolerable interleukin‐2 (IL‐2) regimen (four weekly cycles of human recombinant IL‐2 at 3 × 10 6 U/m 2 /day by continuous infusion for 4 days/week). Sixteen patients completed their induction month of therapy, two had a partial response, six had stable disease, and eight had progressive disease. Four patients had clinical toxicity preventing completion of the induction month of therapy, and one of these patients died during therapy. Significant clinical toxities included decreased performance status, weight gain, catheter‐related thromboses, infectious complications, fever, hypotension, and dyspnea or hypoxemia requiring oxygen. Thus, the addition of LAK cell infusions to this IL‐2 regimen did not cause a noticeable change in antitumor response rate but did cause more severe toxicity.